16.0 REFERENCES 
1. Nilsson F, Jernberg H, Pettersson M. IL-6 as a growth factor 
for human multiple myeloma cells-a short overview. Current Topics 
in Microbiology and Immunology 1991; 166:3-12. 
2. Gore ME, Viner C, Meldrum M, et al. Intensive treatment of 
multiple myeloma and criteria- for -complete, remission,. Lancet 
1989; ii : 879-881 . 
3. Gahrton G, Tura SG, Ljungman P, et al . Allogeneic bone 
marrow transplantation in multiple myeloma. N E J M 1991; ' 
325 : 1267-1273 . 
4. Durie BGM , Salmon SE. A clinical staging system for multiple 
myeloma. Cancer 1975; 36:842-854. 
5. Van Riet I, Heirman C, .Lacor P, De Waele M, Thielmans K. 
Detection of monoclonal B lymphocytes in bone marrow and 
peripheral blood of multiple myeloma patients by immunoglobulin 
gene rearrangement. Brit J Haematol 1989; 73:289-295. 
6. Billadeua D, Blackstadt M, Greipp P, et al. Analysis of B 
lymphoid malignancies using allele-specific PCR: a technique for 
sequential quantitation of residual disease. Blood 1991; in 
press: 
7. Drewinko B, Alexanian R, Boyer H, Bargolie B, Rubinow SI. 
The growth fraction of human myeloma cells. Blood 1981; 57:333. 
8. Potter M. Perspectives on multiple myeloma and plasmacytomas 
in mice. Hematol /Oncol Clin N Amer 1991; in press: 
9. Caligaris-Cappio F, Bergui L, Gregoretti MG, et al. Role of 
bone marrow stromal cells in the growth of human multiple 
myeloma. Blood 1991; 77:2688-2693. 
10. Dewald GW, Kyle "RAT Hicks GA; 'Greipp PR. The clinical 
significance of cytogenetic studies in 100 patients with multiple 
myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 
66:380-390. 
11. Brandt SJ, Bodine DB, Dunbar CE, Nienhuis AW. Dysregulated. 
interleukin 6 expression produces a syndrome resembling 
Castleman's disease in mice. J Clin Invest 1990; 86:592-599. 
12. Suematsu S, Matsude T, Aozasa K, et al . IgGl plasmacytosis 
in interleukin 6 transgenic mice; Proc.Natl Acad Sci USA 1989; 
86:7546-7551. 
[62] 
Recombinant DNA Research, Volume 16 
